Menlo Park, CA – According to filings with the U.S. Securities and Exchange Commission, Hexagon Bio is raising $61,000,001.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Maureen Hillenmeyer played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Hexagon Bio
Hexagon Bio is a data-driven biotech developing targeted small molecule therapeutics. Our proprietary platform combines data science and synthetic biology to discover and engineer drugs from DNA sequences. We are mining fungal genomes for inspiration for the next generation of targeted therapies for diseases with unmet needs.

To learn more about Hexagon Bio, visit http://www.hexagonbio.com/

Contact:
Maureen Hillenmeyer, Chief Executive Officer
650-814-8871
maureen@hexagonbio.com
https://www.linkedin.com/in/maureen-hillenmeyer/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved